Clinical Trials on Radical Antegrade Modular Pancreatosplenectomy in New Zealand
Total 0 results
Nothing found
Sponsors and Collaborators
- Gunkang Pharmaceuticals, Inc
- United States Department of Defense (DOD)
- Foshan Sanshui District People's Hospital
- Foundation for Biosanitary Research and Innovation in Primary Health Care
- Paulo Sérgio Gomes Nogueira Borges
- Oblikue Consulting
- Arsha Vidya Tirtha
- Iyad Naeem Muhammad, PhD
- Rivierduinen, Centre for Personality disorders Jelgersma
- S-Biotek Holding ApS
- Eurotrials Brasil Consultores Cientificos Ltda
- University of Applied Sciences Jena
- Klinik für Allgemein- und Viszeralchirurgie, Department Chirurgie, Luzerner Kantonsspital
- Lilly PharmaceuticalCompany
- Sudimplant SAS - Groupe TBR
- Cardiovascular Center Dedinje, Belgrade, Serbia
- Plethora Solutions Ltd
- 904 Hospital of the People's Liberation Army Joint Logistic Support Force
- Julian Taylor Green
- Korea Otsuka International Asia Arab
- View Full List
Medical Conditions
- Showing the Results of a Program of NHS in Cuiaba_ Brazil
- Bowel Preparation Before Colonoscopy
- Glottic Web of Larynx
- Keratoplasty
- Developmental Dislocation of Hip
- Correction of the Moderate to Severe Nasolabial Folds
- Symptomatic Supraventricular Tachycardia
- Spinocerebellar Ataxia 29
- Monogenic Lupus
- Raynaud Phenomena
- HoFH
- Traumatic Encephalopathy, Chronic
- Hidden Blood Loss
- Coccyx Injury
- Screening Compliance
- Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer
- SCLC
- HOMA-IR
- Outcome After Hepatectomy
- Metastatic Platinum-Resistant Ovarian Carcinoma
- View Full List
Drug Interventions
- Standard medical therapy
- Rovalpituzumab tesirine
- Cytisine
- F520
- Acalabrutinib in combination with VR
- Celecoxib
- Oxycodone
- S-Adenosyl-Methionine
- Ebselen
- Sorafenib
- Bimatoprost 0.03% eye drops
- Pemetrexed
- MMV390048 120mg
- Pegfilgrastim
- Cyanoacrylate
- Vosaroxin
- ABY-035 i.v.
- Recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)
- Furmonertinib 160 mg
- Mineralocorticoid receptor antagonist
- View Full List
CROs by country
- Contract Research Organizations in Albania
- Contract Research Organizations in Brazil
- Contract Research Organizations in Congo
- Contract Research Organizations in Cote d'Ivoire
- Contract Research Organizations in Cyprus
- Contract Research Organizations in El Salvador
- Contract Research Organizations in France
- Contract Research Organizations in Malta
- Contract Research Organizations in Panama
- Contract Research Organizations in Paraguay
- Contract Research Organizations in Slovenia
- Contract Research Organizations in Uganda
- Contract Research Organizations in Venezuela
- CRO list by country